The role of long intergenic noncoding RNA 00511 in malignant tumors: a meta-analysis, database validation and review

Jianlong Ding\textsuperscript{a}, Junyan Cao\textsuperscript{b}, Zhaocong Chen\textsuperscript{c}, and Zhiming He\textsuperscript{d,}\textsuperscript{d}

\textsuperscript{a}Department of Hepatobiliary Surgery, 3201 Hospital of Xi'an Jiaotong University Health Science Center, Shanxi Xi'an, China; \textsuperscript{b}Department of Medical Ultrasonic, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; \textsuperscript{c}Department of Rehabilitation Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; \textsuperscript{d}General Surgery, Chongqing Red Cross Hospital, Jialing No.1 Village, Jiangbei District, Chongqing, China

ABSTRACT
Increasing studies suggested that long intergenic noncoding RNA 00511 (LINC00511) could facilitate the progression of various malignancies and correlates with prognosis of patients with malignant tumors. However, its clinical significance is still not completely clarified. Therefore, we performed a meta-analysis and bioinformatics analysis to further evaluate the correlation of LINC00511 expression level with prognosis and metastasis in patients with tumors. The pooled hazard ratio (HR) with 95% confidence interval (CI) was used to evaluate the prognostic significance of LINC00511 expression level. The pooled odds ratio (OR) with 95% CI was applied to assess the association between LINC00511 expression level and tumor metastasis. A total of 12 studies involving 1040 tumor patients were included in this meta-analysis. The pooled analyses suggested that higher LINC00511 expression level correlated with worse overall survival (OS) (HR = 1.93, 95% CI 1.49–2.49, P < 0.001) and higher incidence of lymph node metastasis (OR = 3.07, 95% CI 2.23–4.23, P < 0.001). Additionally, bioinformatics analysis based on TCGA datasets also showed that increased LINC00511 expression level may predict poor OS and disease-free survival (DFS) in patients with malignant tumors. Taken together, our finding suggested that high LINC00511 expression level may be correlated with poor prognosis and high incidence of metastasis. Nevertheless, further large-scale and high-quality studies are needed to validate our findings.

Background
Cancer is a major cause of death and an essential public health problem worldwide [1]. According to GLOBOCAN 2018, there were approximately 18.1 million new cancer cases and 9.6 million cancer-associated deaths globally in 2018 [2]. Although enormous progress in diagnoses and treatments has improved survival, the long-term outcome of patients with advanced cancer is still...
unfavorable [3]. Therefore, it remains necessary and urgent to explore novel therapeutic targets and prognostic biomarkers for cancers [4].

Long noncoding RNAs (lncRNAs) are non-protein-coding single-stranded RNAs with longer than 200 nucleotides, which play crucial roles in multiple physiological processes, such as transcriptional regulation, posttranscriptional processing and decay of miRNAs, chromatin remodeling and protein degradation [5]. Additionally, mounting evidence shows that many lncRNAs are dysregulated in tumorigenesis and could be exploited as novel therapeutic targets and prognostic biomarkers for cancers [6]. Long intergenic noncoding RNA 00511 (LINC00511) is a newly identified lncRNA and has been reported to be dysregulated in various malignant tumors, including glioma [7], ovarian cancer [8], breast cancer [9,10], cervical cancer [11,12], osteosarcoma [13], lung cancer [14], hepatocellular carcinoma [15–17], renal cell cancer [18], pancreatic cancer [19], gastric cancer [20–22], tongue squamous cell carcinoma [23] and papillary thyroid carcinoma [24]. To date, most literature suggested that LINC00511 was aberrantly upregulated in malignant tumors and its high expression correlated with poor survival of patients with glioma [7], ovarian cancer [8], breast cancer [9,10], cervical cancer [11,12], osteosarcoma [13], lung cancer [14], gastric cancer [22], hepatocellular carcinoma [15], renal cell cancer [18] or pancreatic cancer [19]. Furthermore, those studies revealed that LINC00511 could accelerate tumor progression by inhibiting malignant cell apoptosis and promoting tumor cell proliferation, migration, invasion, metastasis, chemotherapy resistance, and so on [10,11,17].

However, the association between LINC00511 expression and prognosis of patients with malignant tumor is still controversial. For example, Qiao et al. [13] reported that LINC00511 was downregulated in osteosarcoma, which was related to improved survival. Additionally, they further demonstrated that upregulation of LINC00511 could impede the progression of osteosarcoma through inducing apoptosis and suppressing the migration and invasion of osteosarcoma cells [13]. Moreover, the conclusions concerning the clinical role of LINC00511 expression in patients with malignancies in individual studies may be limited by small sample size. Therefore, in this study, we further evaluated the clinical significance of LINC00511 expression in malignant tumors through performing a meta-analysis of the current literatures and conducting a bioinformatics analysis using The Cancer Genome Atlas (TCGA) data. Meanwhile, we also made a comprehensive review of the mechanisms underlying the biological functions of LINC00511 in malignant tumors.

Materials and methods

Search strategy and study selection

We searched PubMed, EMBASE, Web of science, Wanfang and China National Knowledge Infrastructure (CNKI) databases from inception up to July 2020 for eligible studies. The search terms included ‘Long intergenic noncoding RNA 00511’ or ‘LINC00511’. The studies according with the following criteria simultaneously were included: 1) patients were divided into two groups based on LINC00511 expression level; 2) Hazard ratios (HRs) with 95% confidence intervals (CIs) for the association between LINC00511 expression and overall survival (OS) were available; and 3) studies were published in English or Chinese. The exclusion criteria were as following: 1) studies were letters, conference abstracts, meta-analysis or review articles; 2) studies evaluated the prognostic value of LINC00511 expression level using The Cancer Genome Atlas (TCGA) data; or 3) studies enrolled the overlapped patients.

Data extraction and quality assessment

Two authors independently extracted data from eligible studies. Any disagreement was removed by discussion among all the authors. The extracted information covered first author, publication date, country, tumor type, treatment type, sample size, detection method, reference controls, cutoff values, HRs with 95% CIs for OS, survival analysis type and follow-up duration. When HRs were generated using both univariate and multivariate, the HRs from multivariate analysis were preferentially selected due to less confounding factors. If not directly provided in paper, HRs with 95% CIs would be calculated from Kaplan-Meier survival
curves using Engauge Digitizer software. The methodological quality of studies was evaluated using Newcastle-Ottawa scale (NOS) criteria, which is a ‘star’ rating system from 0 to 9 stars [25].

**Validation by analyzing public data**

This study conformed to the publication guidelines established by The Cancer Genome Atlas (TCGA). Gene Expression Profiling Interactive Analysis (GEPIA) was applied to assess the correlations of LINC00511 expression level with OS and DFS. The survival analysis was calculated using the K-M method and log-rank test, and the HRs and p value were presented in the figures of K-M curve as previously described [4].

**Statistical analyses**

All data analyses were conducted using Stata software version 12.0 (Stata Corporation, College Station, TX, USA). HRs with 95% CIs were used to assess the correlation of LINC00511 expression level with OS or DFS. X²-based Cochran Q test and Higgins I² statistic were applied to evaluate the heterogeneity among the eligible studies. P-value < 0.05 or I²-value > 50% indicated the presence of substantial heterogeneity [25]. The random-effect model was chosen when substantial heterogeneity existed. Sensitivity analyses were performed to explore the source heterogeneity and the robustness of the pooled HR for OS. Publication bias was examined by Begg’s funnel plots and Egger’s linear regression tests [25].

**Results**

**Study selection and characteristics**

A total of 304 potentially relevant articles were retrieved from electronic databases. To yield eligible articles, we firstly excluded 128 duplicate articles. After screening the titles and abstracts, we further excluded 98 articles for conference abstracts, review articles and irrelevant-topic studies. Then, 78 articles were screened by full-text. During this step, 66 studies were removed due to insufficient data and TCGA data. Finally, a total of 12 eligible studies were included in this meta-analysis [7–15,18,19]. The flow diagram summarizing the study selection procedure is presented in Figure 1. The main characteristics of eligible studies are summarized in Table 1. All studies enrolled Chinese patients and were published between 2016 and 2020. The sample sizes of eligible studies ranged from 39 to 140. Ten types of cancer were analyzed in

![Flow diagram of the study selection](image-url)
eligible including hepatocellular carcinoma (n = 1), osteosarcoma (n = 1), breast cancer (n = 2), lung cancer (n = 1), glioma (n = 1), ovarian cancer (n = 1), cervical cancer (n = 2), renal cell carcinoma (n = 1), pancreatic cancer (n = 1) and gastric cancer (n = 1). LINC00511 expression levels were detected by RT-qPCR in all the eligible studies. All the included studies were given with no less than six scores based on NOS criteria, suggesting that they were moderate to high quality and eligible for this meta-analysis.

Meta-analysis and bioinformatics analysis of association between LINC00511 expression and survival outcomes

A total of 12 studies, which enrolled 1040 patients with malignant tumors, were included in our meta-analysis to assess the correlation between LINC00511 expression level and OS. Considering the obvious heterogeneity among these studies ($I^2 = 81.9\%, p < 0.01$), we applied the random-effect model to calculate the pooled HR and 95% CI for OS. The result showed that higher LINC00511 expression correlated with worse OS (HR = 1.93, 95% CI 1.49–2.49, P < 0.001) (Figure 2(a)). To date, only two studies reported the relationship between LINC00511 expression and progression-free survival and none of the studies referred to DFS, so we could not conduct a meta-analysis of the prognostic significance of LINC00511 expression for these survival outcomes. To confirm the result of our meta-analysis and evaluate the prognostic significance of LINC00511 expression for the other survival outcomes, we adopted survival plots in GEPIA through merging LINC00511 expression data and survival data of malignancies from all the TCGA dataset, in which 3491 patients were divided into high or low expression group according to LINC00511 expression. The results suggested that higher LINC00511 expression predicted worse OS and DFS (Figure 2(b–c)), further validating the result of our meta-analysis.

Meta-analysis of association between LINC00511 expression and lymph node metastasis

A total of 9 studies with 833 tumor patients were included in this meta-analysis to assess the association between LINC00511 expression and lymph node metastasis. Considering the absence of significant heterogeneity among these studies

---

**Table 1. The main characteristics of studies included in this meta-analysis.**

| Study | Tumor type | Country | Sample size | Follow-up (months) | Treatment | Detection method | Reference controls | Multivariate analysis | NOS score | Reference |
|-------|------------|---------|-------------|-------------------|-----------|----------------|-------------------|---------------------|-----------|-----------|
| Deng, HH 2019 | HCC | China | 49 | NA | Surgery | RT-qPCR | GAPDH | median | HR (95% CI) for OS | 7 | [18] |
| Huang, MS 2020 | BC | China | 80 | NA | Surgery | RT-qPCR | GAPDH | mean | 1.40 (1.02–1.91) | 7 | [19] |
| Liu, LJ 2019 | BC | China | 90 | NA | Surgery | RT-qPCR | GAPDH | mean | 1.44 (1.05–1.92) | 7 | [20] |
| Lu, GM 2018 | BC | China | 39 | NA | Surgery | RT-qPCR | GAPDH | mean | 1.55 (1.12–2.14) | No | [21] |
| Mao, BD 2019 | Glioma | China | 84 | NA | Surgery+ | RT-qPCR | GAPDH | median | 1.46 (1.01–2.11) | Yes | [22] |
| Qiao, SC 2019 | BC | China | 45 | NA | Surgery | RT-qPCR | GAPDH | median | 0.038 (0.006–0.29) | Yes | [23] |
| Sun, SC 2016 | NSCLC | China | 124 | NA | Surgery | RT-qPCR | GAPDH | median | 7.19 (3.53–10.56) | Yes | [24] |
| Wang, B 2019 | OC | China | 80 | NA | Surgery | RT-qPCR | GAPDH | median | 1.69 (1.33–2.09) | No | [25] |
| Wang, J 2019 | BC | China | 82 | NA | Surgery | RT-qPCR | GAPDH | median | 2.53 (1.32–4.19) | Yes | [26] |
| Wang, RP 2019 | HCC | China | 127 | NA | Surgery | RT-qPCR | GAPDH | median | 3.01 (1.26–6.98) | Yes | [27] |
| Zhao, CL 2019 | OC | China | 120 | NA | Surgery | RT-qPCR | GAPDH | median | 2.23 (1.47–3.35) | Yes | [28] |
| Zhao, YF 2018 | PDAC | China | 140 | NA | Surgery | RT-qPCR | GAPDH | median | 2.28 (1.55–3.35) | Yes | [29] |

**Abbreviation:** HR: Hazard ratio; OS: Overall survival; RRC: Renal cell carcinoma; NSCLC: Non-small cell lung cancer; OC: Ovarian cancer; HCC: Hepatocellular carcinoma; PDAC: Pancreatic ductal adenocarcinoma; BIOENGINEERED: Pancreatic ductal adenocarcinoma; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; RT-qPCR: Reverse transcriptase quantitative polymerase chain reaction; NA: Not available; NC: Not calculated; CC: Cervical cancer; BC: Breast cancer; MCC: Malignant mesothelioma; RACC: Renal cell carcinoma; BC: Breast cancer; OC: Ovarian cancer; HCC: Hepatocellular carcinoma; Glioma: Glioma; BC: Breast cancer; PDAC: Pancreatic ductal adenocarcinoma; NOS: Newcastle–Ottawa Scale; DFS: Disease-free survival.
we applied the fixed-effect model to calculate the pooled OR and 95% CI for lymph node metastasis. The result showed that higher LINC00511 expression correlated with higher incidence of lymph node metastasis (OR = 3.07, 95% CI 2.23–4.23, P < 0.001) (Figure 3). To date, only two studies reported the relationship between LINC00511 expression and distant metastasis, so we did not conduct a meta-analysis of the association between LINC00511 expression and distant metastasis due to small sample size.

**Sensitivity analysis and publication bias**

Sensitivity analysis was performed by sequentially omitting single study. As shown in Figure 4(a–b), removal of any individual study had no substantial effects on the pooled HR for OS and the pooled OR for lymph node metastasis. Begg’s funnel plot and Egger’s test were conducted to evaluate the publication bias. The results showed that Begg’s funnel plots for OS and lymph node metastasis were symmetric (Figure 4(c–d)). Moreover, the p values of Egger’s tests for OS and lymph node metastasis were 0.509 and 0.052, respectively. These results suggested that
there was no significant publication bias in our meta-analysis. Overall, our sensitivity analysis and publication bias assessment indicated that our pooled estimations were robust and reliable.

**Discussion**

Numerous studies have suggested that LINC00511 was dysregulated in a multiple of tumors and this
correlated with prognosis and metastasis in human malignancies. However, the conclusions regarding the clinical significance of LINC00511 expression level in malignant tumors remain conflicting, so we performed a meta-analysis and bioinformatics analysis based on The Cancer Genome Atlas (TCGA) data to systematically assess the clinical significance of LINC00511 expression level. Additionally, we also made a comprehensive review of the biological functions of LINC00511 in malignant tumors and the relevant mechanisms. In this study, we found that increased LINC00511 expression was closely associated with worse OS and DFS, as well as higher incidence of lymph node metastasis. Taken together, these findings suggested that LINC00511 might serve as a biomarker for prognosis and metastasis in malignant tumors.

The mechanisms underlying the carcinogenic roles of LINC00511 are rather complex (Table 2 & Figure 5), which may help to explain the clinical significance of LINC00511 expression level in tumors. First, most of studies revealed that LINC00511 could promote the aggressive phenotypes of malignant cells through sponging miRNAs and modulating the expressions of their targets, including miR-625/CCND1 [20], miR-515-5p [21], miR-185-3p/E2 F1/Nanog [10], miR-185/STXBP4 [9], miR-124-3p/CCND2 [26], miR-124-3p/EZH2 [22], miR-524-5p/YB1/ZEBl [27], miR-195/EYA1 [17], miR-424 [15], miR-29 c [28], miR-29b-3p/VEGFA [19], miR-424-5p [29], miR-625-5p/NFIX [20], miR-370-5p [29], miR-765 m/LAMC2 [23], miR-618/MAEL [30], miR-29/CDK6 [28] and miR-765/APE1 [31] pathways. Second, LINC00511 can regulate tumor suppressors or oncopgenes by interacting with DNA methylation-related enzymes and transcriptional factors to facilitate tumor progression. For example, in ER-negative breast cancer, LINC00511 could interact with enhancer of zeste homolog 2 (EZH2) and recruited polycomb repressive complex 2 (PRC2) to methylate lysine 27 on histone H3, which downregulated CDKN1B expression, ultimately facilitating cell cycle progression [32]. It was suggested that LINC00511 could promote the proliferation, invasiveness, metastasis but decreased apoptosis of lung cancer cells by interacting EZH2 to suppress p57 expression via the methylation of lysine 27 on histone H3 of p57 gene [14,33]. Additionally, LINC00511 was also demonstrated to downregulate the expressions of KLF2 and LATS2 by promoting the binding of LSD1 to the promoter regions of LATS2 and KLF2 in lung cancer cells [33]. In thyroid carcinoma, LINC00511 could interact with TAF1 to upregulate JAK2, which then activated STAT3 signaling pathways to maintain the resistance to radiotherapy of malignant cells [34]. In ovarian carcinoma, LINC00511 was able to suppress P21 expression by interacting with EZH2, subsequently inhibiting tumor cell proliferation [35]. Third, LINC00511 can accelerate tumor progression through regulating several tumor-associated signaling pathways such as RXRA/PLD1 [36], PTEN/AKT/FOXO1 [37], p38 [21], ERK1/2 [21] and JNK [21] pathways. Moreover, several studies suggested that LINC00511 could modulate the expressions of multiple proteins related to the aggressive phenotypes of tumor cells [11,24]. Nevertheless, how LINC00511 regulates these tumor-associated signaling pathways and proteins has not been unveiled, which deserves further explorations. Although the vast majority of literature supports the notion that LINC00511 may function as an oncogene, the opposite results were reported in osteosarcoma. Yan et al. [31] and Guo et al. [30] reported that LINC00511 acted as an oncogene in the progression of osteosarcoma. On contrast, Qiao et al. [13] found that high LINC00511 expression correlated with favorable prognosis, and it could impede osteosarcoma progression both in vitro and in vivo. Therefore, further studies are needed to further ascertain the biological functions of LINC00511 in osteosarcoma and the other malignant tumors.

Several limitations should be considered in this meta-analysis. First, all the included studies were retrospective. Second, most of studies did not directly provide HRs for survival outcomes, so we had to calculate HRs based on the Kaplan–Meier survival curves. This manual process may unavoidably cause some calculation errors. Third, there was significant heterogeneity and it may be caused by the complexity and inconsistency in many aspects of the included studies, such as follow-up time, age, gender, and therapy. Fourth, only 12 eligible studies were included into this meta-analysis, suggesting that our conclusions may be still limited by sample size. Additionally, only 1 or 2 eligible studies focused on the specific tumors, so we could not perform the pooled analysis for the specific tumors, which may
| Tumor types                  | Tumor cell lines                                                                 | Expression in tumor tissues and cell lines | Clinical significance of dysregulation                                                                 | Related cell processes                                                                 | Direct or indirect targets | References |
|-----------------------------|---------------------------------------------------------------------------------|------------------------------------------|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------|------------|
| Renal cell cancer           | A498, 786-O, ACHN and Caki-2                                                     | Increased                                | Advanced tumor stage, higher incidence of lymph node metastasis; Worse OS.                             | Facilitate proliferation, colony formation, cell cycle progression, and metastasis, | miR-625/COND1 | [18]      |
|                             |                                                                                 |                                          | and repress apoptosis in vitro; Accelerate tumor growth in vivo.                                     | miR-85-5p; miR-625-5p/NFIX p38, ERK1/2 and JNK, miR-124-3p/EZH2                        |                                         |            |
| Gastric cancer              | AGS, SGC7901, BGC823, MKN45 and MGC803                                         | Increased                                | Advanced tumor stage, Larger tumor size; Worse OS and DFS.                                         | Facilitate tumor cell proliferation, migration and invasion, and repress apoptosis in | miR-515-5p | [20–22]   |
|                             |                                                                                 |                                          | and proliferation in vitro; Accelerate tumor growth in vivo.                                        | vitro; miR-185-3p/625/FL/ Nanog, miR-185-3p/STXBP4, EZH2/PRC2/CDKINB                 |                                         |            |
| Breast cancer               | MDA-MB-231, MDA-MB-436, MDA-MB-468, MDA-MB-453, and MCF-7                      | Increased                                | Higher incidence of lymph node metastasis, distant metastasis and recurrence, larger tumor size, and  | Facilitate proliferation, cell cycle progression, sphere-formation ability, invasion, | miR-124-3p/COND2 | [9,10,28,32]|
|                             |                                                                                 |                                          | advanced tumor stage; Worse OS.                                                                     | resistance to radio therapy and repress apoptosis in vitro; Accelerate tumor growth   | miR-524-3p/CDKINB |            |
|                             |                                                                                 |                                          | in vivo and promote resistance to radio therapy in vivo.                                            | in vivo; miR-195/EYA1, miR-424, miR-29 c                                              |                                         |            |
| Glioma                      | U87, LN229, U251 and A172                                                        | Increased                                | Higher WHO grade and KPS score; Worse OS and DFS.                                                    | Facilitate proliferation, migration, invasion and EMT in vitro; Accelerate tumor     | miR-195/EYA1 | [26,27]   |
| Hepatocellular carcinoma    | SMCC7721, HepG2, Hep3B MHCC-97 H, HuH7, HCC-LM3 and MHCC-97 L                   | Increased                                | Advanced tumor stage, higher incidence of lymph node metastasis and vascular invasion; Worse OS.     | growth in vitro.                                                                     | miR-424 | [15–17]   |
| Pancreatic ductal adenocarcinoma | PANC-1, MIA PaCa-2, Capan-2, SW1990, ASPC-1 and BxPC-3                         | Increased                                | Higher incidence of lymph node metastasis and early recurrence; Worse OS.                           | Facilitate proliferation, migration, invasion and angoiogenesis.                     | miR-29b-3p/VEGFA |            |
| Non-small-cell lung cancer  | A549, SK-MES-1, H1299, 95D, H460, H520, H1975, H157, SK-LU-1, and SPC-A-1       | Increased                                | Large tumor size, Advanced tumor stage, and higher incidence of lymph node metastasis; Worse OS.     | Facilitate proliferation, invasion metastasis, and EMT, and repress apoptosis in     | EZH2/PRC2/p57, PTE/AKT/FOXO1, EZH2/KLF2, EZH2/LATS2, LSDL/LATS2, LSDL1/KLF2, CDR2, CDK4, EZH2, TAF1/JAK2/STAT3 | [14,33,37] |
| Thyroid cancer              | B-CPAP, KTC-1, TPC-1, BCPAP and IH4                                              | Increased                                | Large tumor size and higher incidence of lymph node metastasis                                       | vitro; Accelerate tumor growth in vivo.                                              |                                         |            |
| Ovarian cancer              | CAOV3, OVCAR3, SKOV3, and UWB1.289                                              | Increased                                | Large tumor size, Advanced tumor stage, and higher incidence of lymph node metastasis, poor         | Facilitate proliferation, cell cycle progression, migration, invasion, and            | miR-424-5p, miR-370-5p, EZH2/P21 | [29,35]   |
| Cervical cancer             | SiHa, HeLa, C33A and Caski                                                       | Increased                                | Large tumor size, Advanced tumor stage, and higher incidence of lymph node metastasis, and squamous  | apoptosis and radiosensitivity in vitro.                                              |                                         |            |
|                             |                                                                                 |                                          | cell carcinoma; Worse OS.                                                                          |                                                                                       |                                         |            |

(Continued)
Table 2. (Continued).

| Expression in tumor tissues and cell lines | Tumor types | Tumor cell lines | Clinical significance of dysregulation | Direct or indirect targets | Related cell processes | References |
|------------------------------------------|-------------|-----------------|---------------------------------------|---------------------------|-----------------------|------------|
| Increased                                 | TnG1; SCC-9; and CAL-27 | Tumor cell lines | | miR-765, m/LAMC2 | FACilitate proliferation, colony formation, and migration, and miR-618/MAEL, miR-765/APE1 | [23] |

Conclusion

Increased LINC00511 expression level significantly correlated with worse prognosis and higher incidence of lymph node metastasis in patients with malignant tumors, indicating that LINC00511 may be a prognostic biomarker and therapeutic target. However, our study may overestimate the clinical significance of LINC00511 expression in human malignancies due to several limitations. Therefore, further high-quality studies should be performed to further validate our findings.

Highlight

(1) Role of LINC00511 in tumor

Abbreviations

HR: hazard ratio; CI: confidence interval; OS: overall survival; LncRNA: long noncoding RNA; LINC00511: long intergenic non-protein-coding RNA 511; CCND1: Cyclin D1; E2F1: E2F transcription factor 1; EZH2: enhancer of zeste homolog 2; LSD1: lysine-specific demethylase 1; PRC2: Polycomb repressive complex 2; CDKN1B: cyclin-dependent kinase inhibitor 1B; STXBP4: syntaxin-binding protein 4; CCND2: cyclin D2; ZEB1: zinc finger E-box binding homeobox 1; YB1: Y-box binding protein; YEA1: eyes absent homolog 1; VEGFA: Vascular endothelial growth factor A; LAS2: large tumor suppressor, homolog 2; KLF2: Krueppel-like factor 2; CDK2/4: cyclin-dependent kinase 2/4; TAF1: TATA-box binding protein-associated factor 1; JAK2: Janus kinase 2; STAT3: activating signal transducer and activator of transcription 3; PLD1: Phospholipase D1; RXRA: retinoic X receptor alpha; MMP-2/9: matrix metalloproteinase-2/9; P-GP: P-glycoprotein; MRP1: multidrug resistance protein 1; LAMC2: laminin subunit gamma 2; APE1: apurinic/apyrimidinic endonuclease 1; MAEL: Maelsem; ceRNA: competing endogenous RNA; qPCR: quantitative real-time polymerase chain reaction; TCGA: The Cancer Genome Atlas.

Acknowledgements

None
**Funding**

The study was supported by the National Natural Science Fund of China Grant sponsor: Zhaocong Chen; [Grant no. 81401869]; Medical Scientific Research Foundation of Guangdong Province, China Grant sponsor: Junyan Cao; [Grant no. A2017006].

**Author contributions**

Zhaocong Chen designed this study. Jianlong Ding, Junyan Cao, and Zhiming He were responsible for collecting the data and analyzing and interpreting the data; Jianlong Ding and Zhaocong Chen took charge of drafting the manuscript. All authors read and approved the final manuscript.

**Availability of data and material**

All data generated or analyzed during this study are included in this published article.

**Consent for publication**

The manuscript does not contain data from any individual person.

**Disclosure statement**

All authors declare there is no conflict of interest for this study.

**Ethics approval and consent to participate**

This study is a meta-analysis, so there is unnecessary to provide an Ethical Approval.

**References**

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
[3] Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289.
[4] Hu Y, Zhang Y, Gao J, et al. The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data. Bioengineer. 2020;11(1):572–581.
[5] Jin KT, Yao J-Y, Fang X-L, et al. Roles of lncRNAs in cancer: focusing on angiogenesis. Life Sci. 2020;252:117647.
[6] Han B, Ge Y, Cui J-p, et al. Down-regulation of lncRNA DNAJC3-AS1 inhibits colon cancer via regulating miR-214-3p/LIVIN axis. Bioengineered. 2020;11(1):524–535.

[7] Wang B, Wang Y-Z, Wang K, et al. Expression and clinical significance of lncRNA LINC00511 in plasma exosome of glioma patients. Chin J Pract Nerv Dis. 2019;22(14):1548–1553.

[8] Wang J, Wang S-S, Ma H, et al. Expressions clinical signification and prognostic analysis of linc00511 in ovarian cancer tissues. J Pract Med. 2019;35(16):2584–2591.

[9] Liu L, Zhu Y, Liu A-M, et al. Long noncoding RNA LINC00511 involves in breast cancer recurrence and radio-resistance by regulating STXB4 expression via miR-185. Eur Rev Med Pharmacol Sci. 2019;23(17):7457–7468.

[10] Lu G, Li Y, Ma Y, et al. Long noncoding RNA LINC00511 contributes to breast cancer tumorigenesis and stemness by inducing the miR-185-3p/E2F1/ Nanog axis. J Exp Clin Cancer Res. 2018;37(1):289.

[11] Mao B-DI, Xu P, Zhong Y, et al. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J Biosci. 2019;44(2):44.

[12] Yu C-L, Xu X-L, Yuan F. LINC00511 is associated with the malignant status and promotes cell proliferation and motility in cervical cancer. Biosci Rep. 2019;39(9):BSR20190903.

[13] Qiao S-C, Qi K, Liu C, et al. Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo. J Clin Lab Anal. 2020;34(5):e23164.

[14] Sun C-C, Li S-J, Li G, et al. Long intergenic noncoding RNA 00511 acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Nucleic Acids. 2016;5(11):e385–e385.

[15] Wang RP, Jiang J, Jiang T, et al. Increased long noncoding RNA LINC00511 is correlated with poor prognosis and contributes to cell proliferation and metastasis by modulating miR-424 in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2019;23(8):3291–3301.

[16] Hu P, Cui H, Lei T, et al. Linc00511 indicates a poor prognosis of liver hepatocellular carcinoma. Onco Targets Ther. 2019;12:9367–9376.

[17] Hu W-Y, Wei H-Y, Li K-M, et al. LINC00511 as a ceRNA promotes cell malignant behaviors and correlates with prognosis of hepatocellular carcinoma patients by modulating miR-195/EYA1 axis. Biomed Pharmacother. 2020;121:109642.

[18] Deng H, Huang C, Wang Y, et al. LINC00511 promotes the malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-625 and thereby increasing cyclin D1 expression. Aging (Albany NY). 2019;11(16):5975–5991.

[19] Zhao X, Liu Y, Li Z, et al. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2018;22(1):655–667.

[20] Chen Z, Wu H, Zhang Z, et al. LINC00511 accelerated the process of gastric cancer by targeting miR-625-5p/NFIX axis. Cancer Cell Int. 2019;19:351.

[21] Wang D, Liu K, Chen E. LINC00511 promotes proliferation and invasion by sponging miR-515-5p in gastric cancer. Cell Mol Biol Lett. 2020;25:4.

[22] Huang HG, Tang X-L, Huang X-S, et al. Long noncoding RNA LINC00511 promoted cell proliferation and invasion via regulating miR-124-3p/EZH2 pathway in gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24(8):4232–4245.

[23] Ding J, Yang C, Yang S. LINC00511 interacts with miR-765 and modulates tongue squamous cell carcinoma progression by targeting LAMC2. J Oral Pathol Med. 2018;47(5):468–476.

[24] Xiang J, Guan Y, Bhandari A, et al. LINC00511 influences cellular proliferation through cyclin-dependent kinases in papillary thyroid carcinoma. J Cancer. 2020;11(2):450–459.

[25] Fan Y, Chen J. Clinopathological significance of survivin expression in patients with cervical cancer: A systematic meta-analysis. Bioengineered. 2017;8(5):511–523.

[26] Li C, Liu H, Yang J, et al. Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR-124-3p/CCND2 axis. J Cell Mol Med. 2019;23(6):4386–4394.

[27] Du X, Tu Y, Liu S, et al. LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop. J Cell Mol Med. 2020;24(2):1474–1487.

[28] Zhang H, Zhao B, Wang X, et al. LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis. Life Sci. 2019;228:135–144.

[29] Wang K, Zhu G, Bao S, et al. Long non-coding RNA LINC00511 mediates the effects of ESR1 on proliferation and invasion of ovarian cancer through miR-424-5p and miR-370-5p. Cancer Manag Res. 2019;11:10807–10819.

[30] Guo W, Yu Q, Zhang M, et al. Long intergenic non-protein coding RNA 511 promotes the progression of osteosarcoma cells through sponging microRNA 618 to upregulate the expression of maelstrom. Aging (Albany NY). 2019;11(15):5351–5367.

[31] Yan L-H, Wu X-K, Liu Y-X, et al. LncRNA Linc00511 promotes osteosarcoma cell proliferation and migration through sponging miR-765. J Cell Biochem. 2018. DOI:10.1002/jcb.27999

[32] Zhang J, Sui S, Wu H, et al. The transcriptional landscape of lncRNAs reveals the oncogenic function of LINC00511 in ER-negative breast cancer. Cell Death Dis. 2019;10(8):599.

[33] Zhu FY, Zhang S-R, Wang L-H, et al. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1. Eur Rev Med Pharmacol Sci. 2019;23(19):8377–8390.
[34] Chen Y, Bao C, Zhang X, et al. Knockdown of LINC00511 promotes radiosensitivity of thyroid carcinoma cells via suppressing JAK2/STAT3 signaling pathway. Cancer Biol Ther. 2019;20(9):1249–1257.

[35] Wang J, Tian Y, Zheng H, et al. An integrated analysis reveals the oncogenic function of IncRNA LINC00511 in human ovarian cancer. Cancer Med. 2019;8(6):3026–3035.

[36] Shi Y, Liu M, Huang Y, et al. Promotion of cell autophagy and apoptosis in cervical cancer by inhibition of long noncoding RNA LINC00511 via transcription factor RXRA-regulated PLD1. J Cell Physiol. 2020. DOI:10.1002/jcp.29529

[37] Jiang L, Xie X, Ding F, et al. Silencing LINC00511 inhibits cell proliferation, migration and EMT via PTEN/AKT/FOXO1 signaling pathway in lung cancer. Biochem Cell Biol. 2019. DOI:10.1139/bcb-2018-0364